|
Match
|
Document |
Document Title |
|
|
7318925 |
Methods of use for antibodies against parathyroid hormone
Embodiments of the invention described herein relate to antibodies directed to the antigen parathyroid hormone (PTH) and uses of such antibodies. In particular, in some embodiments, there are...
|
|
|
7311913 |
Methods of treating thrombotic diseases with von Willebrand factor specific antibodies
Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.
|
|
|
7304144 |
Antibodies binding to human TSLP Polypeptides
The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
7297336 |
Factor IXa specific antibodies displaying factor VIIIa like activity
Ligands such as antibodies that can bind factor IX/factor IXa and increase the procoagulant activity of factor IXa (FIXa), pharmaceutical compositions containing such ligands, methods for treating...
|
|
|
7291333 |
Blockade of protein C activation reduces microvascular surgical blood loss
A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of...
|
|
|
7288250 |
Monoclonal antibodies against HMGB1
In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting...
|
|
|
7285269 |
Antibodies directed to tumor necrosis factor
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid...
|
|
|
7282206 |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
Methods are provided for treating or inhibiting the formation of tissue fibrosis using IL-13 antagonists, including without limitation soluble forms of the IL-13 receptor.
|
|
|
7279157 |
Method for treating psoriasis by administering an anti-il-12 antibody
The present invention relates to an anti-IL-12 antibody, including isolated nucleic acids that encode an anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or plants, and methods...
|
|
|
7279161 |
Factor IX/factor IXa activating antibodies and antibody derivatives
An antibody or antibody derivative against factor IX/activated factor IX (FIXa) which increases the procoagulant activity of FIXa.
|
|
|
7279158 |
Methods for the treatment of inflammatory joint disease
The use of compounds that block complement component C5 or its active fragments C5 a and/or C5 b (such compounds collectively referred to as “C5 blockers”) to treat established joint...
|
|
|
7276238 |
Methods for using chemokine teck
Novel chemokines from mammals, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said chemokines. Chemokine receptors are also provided. Methods...
|
|
|
7276239 |
Recombinant A2-specific TNFα-specific antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7273925 |
Methods and products for regulating lectin complement pathway associated complement activation
The invention relates to methods and products for regulating lectin complement pathway associated complement activation. The methods include both in vitro and in vivo methods for inhibiting lectin...
|
|
|
7264801 |
EG-VEGF nucleic acids and polypeptides and method of use
The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells...
|
|
|
7264803 |
Methods and pharmaceutical formulations for the treatment of pulmonary hypertension
A method of treating pulmonary hypertension in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to treat the pulmonary hypertension in...
|
|
|
7261890 |
Methods for using canine immunoglobulin variable domains and caninized antibodies
The present invention provides canine heavy chain and light chain (both λ and κ) variable domain nucleic acids and polypeptides. The present invention also provides caninized antibodies comprised...
|
|
|
7261893 |
Neutralizing antibodies against GDF-8 and uses therefor
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in...
|
|
|
7261894 |
Methods of treating inflammatory and/or autoimmune disease
The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such...
|
|
|
7261891 |
Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
Methods are described for treating inflammatory bowel disease in animals, including humans. Specific avian polyclonal antibodies directed to proinflammatory cytokines (such as IL-6 and TNF) are...
|
|
|
RE39789 |
Tumor therapy
Neoplasia is treated by administering to a mammalian host a composition comprising ligands for the NKG2D receptor. In addition, other NKG2D ligands, proteins specific for the neoplastic cells and...
|
|
|
7256273 |
Humanized antibodies that recognize beta amyloid peptide
The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.
|
|
|
7255854 |
Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
Compositions and methods comprising “lymphotoxin-β receptor blocking agents” which block lymphotoxin-β receptor signaling and are useful for altering immunological diseases, and particularly...
|
|
|
7252822 |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist
The invention features methods and compositions for preventing or treating pain resulting from surgery or an incision by administering an antagonist of nerve growth factor (NGF). The NGF antagonist...
|
|
|
7250165 |
Anti-TNF antibodies, compositions, methods and uses
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or...
|
|
|
7250168 |
Tissue factor targeted thrombomodulin fusion proteins as anticoagulants
This invention relates to novel fusion proteins which are comprised of a targeting protein that binds tissue factor (TF), which is operably linked to the thrombomodulin (TM) EGF456 domain alone or...
|
|
|
7247304 |
Methods of treating using anti-IL-15 antibodies
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced...
|
|
|
7247711 |
IL-23p40 specific antibody
Novel anti-IL-23p40 specific human Ig derived proteins, including, without limitation, antibodies, fusion proteins, and mimetibodies, isolated nucleic acids that encode the anti-IL-23p40 Ig derived...
|
|
|
7244707 |
Regulation of cytotrophoblast cell differentiation and cell migration
The present invention is predicated on the discovery of certain interactions between cellular growth factors and opposing actions that control differentiation and migration or invasion of...
|
|
|
7238729 |
Silica mesoporous aerogels having three-dimensional nanoarchitecture with colloidal gold-protein superstructures nanoglued therein
This disclosure describes the first viable non-enzyme protein encapsulated within an aerogel. In this, a large excess of cyt c is added to a commercial buffered Au sol solution ( ) which results in...
|
|
|
7235239 |
Antibodies to a chemokine expressed in inflamed adenoid
The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for...
|
|
|
7226593 |
Methods of treating cachexia with chimeric anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α(TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7226594 |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
A novel gene 0161P2F10B (also designated 161P2F10B) and its encoded protein, and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is...
|
|
|
7223396 |
Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7223394 |
Human antibodies that bind human TNFα
Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K d...
|
|
|
7220413 |
Pharmaceutical composition containing inhibitors of interferon-γ
The present invention provides compositions and methods for promoting the healing of wounds or fibrotic disorders with reduced scarring, comprising inhibitors and inhibiting IFN-γ, together with...
|
|
|
7214785 |
Human-type anti-blood coagulation factor VIII antibody
The present invention provides a human antibody against blood coagulation factor VIII (hereinafter also referred to as “FVIII”) and an antibody fragment that binds to human FVIII and...
|
|
|
7214375 |
Methods of decreasing the accumulation of extracellular matrix associated with glomerulonephritis with anti-TGF-β-specific antibodies
The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress...
|
|
|
7214658 |
Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
The present invention provides specific methods of using and administering etanercept to improve cognitive function in a human, for both the treatment and prevention of cognitive impairment, or,...
|
|
|
7214376 |
Methods of inhibiting TNFα in patients with neoplastic disease
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7208153 |
Method for the improvement of neuronal regeneration
A method for the improvement of neuronal regeneration by prevention or inhibition of basal membrane formation induced by a lesion of neuronal tissue.
|
|
|
7204985 |
Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
RE39548 |
Interleukin-5 specific recombinant antibodies
An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
|
|
|
7198790 |
Growth differentiation factor-5
Growth differentiation factor-5 (GDF-5) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-5...
|
|
|
7192583 |
Methods for modulating bone mineralization
Antibodies to a novel family of TGF-β binding proteins are disclosed, for use in methods of altering bone density and bone mineralization, which methods are applicable to the treatment of diseases...
|
|
|
7192584 |
Methods of treating psoriasis with anti-TNF antibodies
The invention relates to anti-TNF antibodies, fragments, regions and derivatives thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in methods of treating...
|
|
|
7192917 |
Antagonists of HMG1 for treating inflammatory conditions
There is disclosed a pharmaceutical composition and method for treating sepsis, including, septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount...
|
|
|
7189820 |
Antibodies against tumor necrosis factor delta (APRIL)
The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and...
|
|
|
7179466 |
Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated...
|
|
|
7179463 |
Treatment of alzheimer's disease
A method for the treatment of Alzheimer's disease in a subject having or suspected of having Alzheimer's disease by administering to the subject a therapeutically effective amount of an antibody...
|